Phase II Randomized Study to Evaluate Safety and Efficacy of MK7009 Administered With Pegylated-Interferon and Ribavirin in Japanese Treatment-Experienced Patients With Chronic Hepatitis C Infection.

Trial Profile

Phase II Randomized Study to Evaluate Safety and Efficacy of MK7009 Administered With Pegylated-Interferon and Ribavirin in Japanese Treatment-Experienced Patients With Chronic Hepatitis C Infection.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Vaniprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 10 Apr 2012 Actual patient number is 90 as reported by ClinicalTrials.gov.
    • 22 Mar 2012 Actual end date (Feb 2012) added as reported by ClinicalTrials.gov.
    • 22 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top